Psilocybin as a tool for enhancing cognitive flexibility
This interventional trial (n=60), conducted by the University Maastricht (UM), investigates the effects of psilocybin (12mg/70kg) on cognitive flexibility, specifically divergent thinking and goal-directed behaviour.
Details
Randomised, double-blind, placebo-controlled parallel design in healthy volunteers (n=60) assessing a single oral dose of psilocybin (0.17 mg/kg) versus placebo on divergent thinking and goal-directed versus habitual behaviour with stress induction.
Outcomes include behavioural measures of divergent thinking and goal-directed behaviour, cortical–subcortical functional connectivity and neurotransmission (GABA and glutamate), subjective experience, pharmacokinetics and cortisol. Acute measurements up to 360 minutes post-dose and follow-up testing on day two (~150 minutes).